|
GB8808015D0
(en)
|
1988-04-06 |
1988-05-05 |
Ritter M A |
Chemical compounds
|
|
WO1990005183A1
(en)
|
1988-10-31 |
1990-05-17 |
Immunex Corporation |
Interleukin-4 receptors
|
|
BR9205967A
(pt)
|
1991-05-03 |
1994-07-26 |
Seragen Inc |
Moléculas marcadas com receptor de interleucina tratamento de artrite inflamatória
|
|
JP3315427B2
(ja)
|
1992-03-05 |
2002-08-19 |
大日本除蟲菊株式会社 |
皮膚炎治療剤
|
|
US5714146A
(en)
|
1992-08-26 |
1998-02-03 |
Board Of Regents Of The University Of Washington |
IL-4 bone therapy
|
|
EP0604693A1
(en)
|
1992-12-29 |
1994-07-06 |
Schering-Plough |
Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
|
|
ZA946875B
(en)
|
1993-09-07 |
1995-07-06 |
Smithkline Beecham Corp |
Recombinant il4 antibodies useful in treatment of il4 mediated disorders
|
|
AU766492B2
(en)
|
1998-09-18 |
2003-10-16 |
Dynavax Technologies Corporation |
Methods of treating IgE-associated disorders and compositions for use therein
|
|
US6927044B2
(en)
|
1998-09-25 |
2005-08-09 |
Regeneron Pharmaceuticals, Inc. |
IL-1 receptor based cytokine traps
|
|
WO2001092340A2
(en)
|
2000-05-26 |
2001-12-06 |
Immunex Corporation |
Use of interleukin-4 antagonists and compositions thereof
|
|
US7879328B2
(en)
|
2000-06-16 |
2011-02-01 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator
|
|
AU2001267917A1
(en)
|
2000-07-26 |
2002-02-05 |
Kenjirou Tsuchida |
Antipruritic compositions and compositions promoting wound healing
|
|
RU2283665C2
(ru)
|
2000-12-22 |
2006-09-20 |
Сосьете Де Продюи Нестле С.А. |
Индуцирование толерантности
|
|
US20030103938A1
(en)
|
2001-05-09 |
2003-06-05 |
Alk-Abello A/S |
Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
|
|
US20050031609A1
(en)
|
2001-05-11 |
2005-02-10 |
Thomas Hultsch |
Compositions for use in treating ige-associated disorders
|
|
CA2447795A1
(en)
|
2001-05-23 |
2002-11-28 |
Duotol Ab |
Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
|
|
AU2002357770B2
(en)
|
2001-11-30 |
2008-07-31 |
Biogen Ma Inc. |
Antibodies against monocyte chemotactic proteins
|
|
ATE435239T1
(de)
|
2002-03-29 |
2009-07-15 |
Schering Corp |
Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
|
|
WO2004047793A1
(en)
|
2002-11-26 |
2004-06-10 |
Alk-Abelló A/S |
Pharmaceutical allergen product
|
|
EP1592777A4
(en)
|
2003-02-01 |
2008-06-04 |
Tanox Inc |
METHOD OF GENERATING HIGH-ANTIBODY ANTIBODIES
|
|
US7923209B2
(en)
|
2003-03-14 |
2011-04-12 |
Anergis, S.A. |
Allergen peptide fragments and use thereof
|
|
NZ547588A
(en)
|
2003-11-07 |
2009-05-31 |
Immunex Corp |
Antibodies that bind interleukin-4 receptor
|
|
CA2550933A1
(en)
|
2003-12-22 |
2005-07-14 |
Amgen Inc. |
Methods for identifying functional antibodies
|
|
EP1723173B1
(en)
|
2004-02-27 |
2008-05-14 |
Regeneron Pharmaceuticals, Inc. |
Il-4/il-13 specific polypeptides and therapeutic uses thereof
|
|
AR049390A1
(es)
*
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
|
US20090098142A1
(en)
|
2004-06-09 |
2009-04-16 |
Kasaian Marion T |
Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
|
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
|
JP5234445B2
(ja)
|
2004-10-05 |
2013-07-10 |
源一郎 杣 |
薬剤
|
|
WO2006083390A2
(en)
|
2004-12-07 |
2006-08-10 |
Children's Hospital Medical Center |
Eotaxin-3 in eosinophilic esophagitis
|
|
TW200902555A
(en)
|
2005-01-03 |
2009-01-16 |
Hoffmann La Roche |
Antibodies against IL-13 receptor alpha 1 and uses thereof
|
|
BRPI0611069A2
(pt)
|
2005-05-06 |
2010-11-09 |
Zymogenetics Inc |
anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma
|
|
US8679545B2
(en)
|
2005-11-12 |
2014-03-25 |
The Regents Of The University Of California |
Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
|
|
US8324192B2
(en)
|
2005-11-12 |
2012-12-04 |
The Regents Of The University Of California |
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
|
|
NZ587107A
(en)
|
2006-06-02 |
2012-05-25 |
Regeneron Pharma |
High affinity antibodies to human il-6 receptor
|
|
JP4221018B2
(ja)
|
2006-08-31 |
2009-02-12 |
トヨタ自動車株式会社 |
頭部保護エアバッグ装置
|
|
LT2769992T
(lt)
|
2006-10-02 |
2021-04-12 |
Regeneron Pharmaceuticals, Inc. |
Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių
|
|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
SI2132230T1
(sl)
|
2007-03-22 |
2014-07-31 |
Genentech, Inc. |
Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE
|
|
EP2022507A1
(en)
|
2007-08-07 |
2009-02-11 |
Universität Hamburg |
Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
|
|
US8637239B2
(en)
|
2007-11-05 |
2014-01-28 |
The Board Of Trustees Of The University Of Illinois |
Minimally-invasive measurement of esophageal inflammation
|
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
|
DE202008006598U1
(de)
|
2008-04-11 |
2008-10-02 |
Alk-Abelló A/S |
Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
|
|
US20090264392A1
(en)
|
2008-04-21 |
2009-10-22 |
Meritage Pharma, Inc. |
Treating eosinophilic esophagitis
|
|
US20110301046A1
(en)
|
2008-12-01 |
2011-12-08 |
Children's Hospital Medical Center |
Methods of Determining Efficacy of Glucocorticoid Treatment of Eosinophilic Esophagitis
|
|
US20120088814A1
(en)
|
2009-03-31 |
2012-04-12 |
Isis Pharmaceuticals, Inc. |
Methods of modulating an immune response to a viral infection
|
|
US8497528B2
(en)
|
2010-05-06 |
2013-07-30 |
Taiwan Semiconductor Manufacturing Company, Ltd. |
Method for fabricating a strained structure
|
|
BR112012005117A2
(pt)
|
2009-09-07 |
2016-05-03 |
Dbv Tech |
método de tratamento de esofagite eosinofílica
|
|
US8993347B2
(en)
*
|
2009-12-17 |
2015-03-31 |
Cornell University |
Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
|
|
ES2894936T3
(es)
|
2010-06-24 |
2022-02-16 |
Viropharma Biologics Llc |
Métodos de tratamiento para la inflamación del esófago
|
|
CN106267189B
(zh)
|
2010-10-06 |
2021-02-26 |
瑞泽恩制药公司 |
含有抗白介素-4受体(il-4r)的抗体的稳定制剂
|
|
KR101962483B1
(ko)
|
2010-11-17 |
2019-03-29 |
추가이 세이야쿠 가부시키가이샤 |
혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
|
|
RU2453303C1
(ru)
|
2010-12-23 |
2012-06-20 |
Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") |
Фармацевтическая композиция для лечения атопического дерматита
|
|
WO2012094643A2
(en)
|
2011-01-06 |
2012-07-12 |
Children's Hospital Medical Center |
Esophageal cytokine expression profiles in eosinophilic esophagitis
|
|
US20130052190A1
(en)
|
2011-02-22 |
2013-02-28 |
Oxagen Limited |
CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
|
|
EP2723899B1
(en)
|
2011-06-21 |
2020-11-18 |
Children's Hospital Medical Center |
Diagnostic methods for eosinophilic esophagitis
|
|
US8790651B2
(en)
|
2011-07-21 |
2014-07-29 |
Zoetis Llc |
Interleukin-31 monoclonal antibody
|
|
US20140303067A1
(en)
|
2011-10-06 |
2014-10-09 |
N.V. Nutricia |
Treatment of eosinophilic esophagitis
|
|
KR20140113667A
(ko)
|
2011-12-16 |
2014-09-24 |
아토픽스 테라퓨릭스 리미티드 |
호산구성 식도염의 치료를 위한 ｃｒｔｈ2 길항제 및 양성자 펌프 저해제의 조합
|
|
US20130243750A1
(en)
|
2012-01-31 |
2013-09-19 |
Genentech, Inc. |
Anti-ige antibodies and methods using same
|
|
WO2013155010A1
(en)
|
2012-04-09 |
2013-10-17 |
Children's Hospital Medical Center |
Non-invasive biomarkers for eosinophilic esophagitis
|
|
IL312711A
(en)
|
2012-08-21 |
2024-07-01 |
Regeneron Pharma |
Methods for the treatment or prevention of asthma through the administration of an antagonist to 4R-IL
|
|
KR102576903B1
(ko)
*
|
2012-09-07 |
2023-09-13 |
리제너론 파아마슈티컬스, 인크. |
Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
|
|
US10132809B2
(en)
|
2012-10-10 |
2018-11-20 |
Rhote Island Hospital |
Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
|
|
US9963513B2
(en)
|
2013-02-05 |
2018-05-08 |
Engmab Sàrl |
Method for the selection of antibodies against BCMA
|
|
TWI755763B
(zh)
|
2013-06-04 |
2022-02-21 |
美商再生元醫藥公司 |
藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
|
|
KR20210132232A
(ko)
*
|
2013-06-21 |
2021-11-03 |
사노피 바이오테크놀로지 |
Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
|
|
TWI634900B
(zh)
|
2013-07-11 |
2018-09-11 |
再生元醫藥公司 |
藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
|
|
RU2552929C1
(ru)
|
2013-11-14 |
2015-06-10 |
Общество С Ограниченной Ответственностью "Фарминтерпрайсез" |
Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
|
|
IL315136A
(en)
|
2014-02-21 |
2024-10-01 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4rantagonist
|
|
KR102927870B1
(ko)
|
2014-02-28 |
2026-02-19 |
리제너론 파아마슈티컬스, 인크. |
Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
|
|
WO2016077675A1
(en)
|
2014-11-14 |
2016-05-19 |
Sanofi Biotechnology |
Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
|
|
AU2017220184B2
(en)
*
|
2016-02-19 |
2024-04-18 |
Regeneron Pharmaceuticals, Inc. |
Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
|
|
TWI777515B
(zh)
|
2016-08-18 |
2022-09-11 |
美商愛戴爾製藥股份有限公司 |
治療嗜伊紅性食道炎之方法
|
|
US11771743B2
(en)
|
2016-09-01 |
2023-10-03 |
Regeneron Pharmaceuticals, Inc. |
Methods for preventing or treating allergy by administering an IL-4R antagonist
|
|
KR20190053250A
(ko)
|
2016-09-22 |
2019-05-17 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법
|
|
US10485844B2
(en)
|
2016-09-22 |
2019-11-26 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
|
|
JP2020507605A
(ja)
|
2017-02-17 |
2020-03-12 |
フレッド ハッチンソン キャンサー リサーチ センター |
Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
WO2019028367A1
(en)
|
2017-08-04 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
|
|
EP3703818B1
(en)
|
2017-10-30 |
2023-11-01 |
Sanofi Biotechnology |
Il-4r antagonist for use in a method for treating or preventing asthma
|
|
MA52624A
(fr)
|
2018-05-13 |
2021-03-24 |
Regeneron Pharma |
Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
|
|
JPWO2019240288A1
(ja)
|
2018-06-14 |
2021-07-26 |
味の素株式会社 |
抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩
|
|
SG11202109002XA
(en)
|
2019-03-21 |
2021-09-29 |
Regeneron Pharma |
Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
|
|
KR20220004708A
(ko)
|
2019-05-01 |
2022-01-11 |
사노피 바이오테크놀로지 |
Il-33 길항제를 투여하여 천식을 치료 또는 예방하는 방법
|
|
AU2020325021B2
(en)
|
2019-08-05 |
2024-05-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
|
|
EP4010373A1
(en)
|
2019-08-05 |
2022-06-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
IL293487A
(en)
|
2019-12-09 |
2022-08-01 |
Sanofi Biotechnology |
Methods for the treatment of digitally identified il-4/il-13-related disorders
|
|
KR20220158821A
(ko)
|
2020-03-27 |
2022-12-01 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
|
|
IL298257A
(en)
|
2020-05-22 |
2023-01-01 |
Regeneron Pharma |
Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
|
|
MX2023003942A
(es)
|
2020-10-05 |
2023-06-02 |
Sanofi Biotechnology |
Metodos para el tratamiento del asma en sujetos pediatricos mediante la administracion de un antagonista del il-4r.
|
|
MX2023007945A
(es)
|
2021-01-08 |
2023-09-21 |
Regeneron Pharma |
Metodos para tratar la alergia al cacahuate y mejorar la inmunoterapia especifica de alergeno del cacahuate mediante la administracion de un antagonista de il-4r.
|